Prelude Therapeutics Company Insiders
PRLD Stock | USD 1.05 0.01 0.94% |
Prelude Therapeutics employs about 128 people. The company is managed by 14 executives with a total tenure of roughly 299 years, averaging almost 21.0 years of service per executive, having 9.14 employees per reported executive. Evaluation of Prelude Therapeutics' management performance can provide insight into the firm performance.
Prelude |
Prelude Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3929) % which means that it has lost $0.3929 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6664) %, meaning that it created substantial loss on money invested by shareholders. Prelude Therapeutics' management efficiency ratios could be used to measure how well Prelude Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Prelude Therapeutics Workforce Comparison
Prelude Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,324. Prelude Therapeutics holds roughly 128 in number of employees claiming about 6% of equities under Health Care industry.
Prelude Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prelude Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prelude Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Prelude Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Prelude Therapeutics Notable Stakeholders
A Prelude Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Prelude Therapeutics often face trade-offs trying to please all of them. Prelude Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Prelude Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Edna MD | President Officer | Profile | |
Laurent MBA | Chief Officer | Profile | |
William MD | Senior Development | Profile | |
Naveen Babbar | Senior Medicine | Profile | |
Neelesh MD | VP Devel | Profile | |
Aimee Crombie | Senior Operations | Profile | |
Madhu Pudipeddi | Senior Operations | Profile | |
Lindsey Trickett | Vice Relations | Profile | |
Michele MBA | Chief Officer | Profile | |
Krishna DVM | CEO Founder | Profile | |
Peggy Scherle | Chief Officer | Profile | |
Laurent Chardonnet | Chief Officer | Profile | |
Bryant JD | Chief Secretary | Profile | |
Andrew Combs | Executive Chemistry | Profile |
About Prelude Therapeutics Management Performance
The success or failure of an entity such as Prelude Therapeutics often depends on how effective the management is. Prelude Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Prelude management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Prelude management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware. Prelude Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 112 people.
Please note, the presentation of Prelude Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Prelude Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Prelude Therapeutics' management manipulating its earnings.
Prelude Therapeutics Workforce Analysis
Traditionally, organizations such as Prelude Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Prelude Therapeutics within its industry.Prelude Therapeutics Manpower Efficiency
Return on Prelude Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 951.8K | |
Net Loss Per Executive | 8.7M | |
Working Capital Per Employee | 1.7M | |
Working Capital Per Executive | 15.3M |
Complementary Tools for Prelude Stock analysis
When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Transaction History View history of all your transactions and understand their impact on performance | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |